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Background: Existing predictive models for lung cancer focus on 
improving screening or referral for biopsy in general medical popu-
lations. A predictive model calibrated for use during preoperative 
evaluation of suspicious lung lesions is needed to reduce unneces-
sary operations for a benign disease. A clinical prediction model 
(Thoracic Research Evaluation And Treatment [TREAT]) is pro-
posed for this purpose.
Methods: We developed and internally validated a clinical predic-
tion model for lung cancer in a prospective cohort evaluated at our 
institution. Best statistical practices were used to construct, evaluate, 
and validate the logistic regression model in the presence of missing 
covariate data using bootstrap and optimism corrected techniques. 
The TREAT model was externally validated in a retrospectively col-
lected Veteran Affairs population. The discrimination and calibra-
tion of the model was estimated and compared with the Mayo Clinic 
model in both the populations.
Results: The TREAT model was developed in 492 patients from 
Vanderbilt whose lung cancer prevalence was 72% and validated 
among 226 Veteran Affairs patients with a lung cancer prevalence of 
93%. In the development cohort, the area under the receiver operat-
ing curve (AUC) and Brier score were 0.87 (95% confidence interval 
[CI], 0.83–0.92) and 0.12, respectively compared with the AUC 0.89 
(95% CI, 0.79–0.98) and Brier score 0.13 in the validation dataset. 
The TREAT model had significantly higher accuracy (p < 0.001) and 
better calibration than the Mayo Clinic model (AUC = 0.80; 95% CI, 
75–85; Brier score = 0.17).
Conclusion: The validated TREAT model had better diagnostic 
accuracy than the Mayo Clinic model in preoperative assessment 
of suspicious lung lesions in a population being evaluated for lung 
resection.
Key Words: Lung cancer, Diagnosis, Prediction models.
(J Thorac Oncol. 2014;9: 1477–1484)
Lung cancer is the leading cause of cancer-related mortal-ity in the United States,1,2 but early detection and treat-
ment prolongs life. The National Lung Screening Trial 
found a 20% reduction in lung cancer mortality in high-risk 
patients screened with low-dose computed tomography (CT). 
Implementation of a screening regimen for lung cancer among 
the estimated 7.4 million eligible Americans3 will greatly 
increase the number of lung nodules requiring evaluation and 
diagnosis. In addition, 39% of the patients screened with low-
dose CT had at least one positive scan requiring additional 
diagnostic evaluations.4 A diagnostic operation after nodule 
discovery and radiographic surveillance resulted in a benign 
diagnosis in 24% of the surgical procedures. Other stud-
ies describing resection for known or suspected lung cancer 
report benign disease rates as high as 40%.5–9
Existing lung cancer prediction models are designed to 
either determine which high-risk populations would most ben-
efit from screening10–13; or estimate the likelihood of cancer, 
once a lesion is discovered.14–16 Current guidelines from the 
American College of Chest Physicians recommend that cli-
nicians use a validated prediction model, such as the model 
developed in the Mayo Clinic, or their clinical expertise to 
estimate the probability of cancer in a suspicious lung lesion.17 
The Mayo Clinic model contains six variables (age, smoking 
history, previous cancer, lesion size, spiculated edge, and loca-
tion) and was designed to evaluate nodules in patients selected 
from a general population who had a lesion found on imaging. 
Our previous work demonstrated that the Mayo Clinic model 
has poor calibration in patients referred for surgical evalua-
tion.18 Currently, no models exist to estimate the lesion’s prob-
ability of malignancy at the point of surgical evaluation.
Patients evaluated by surgeons usually have a signifi-
cant body of diagnostic information compiled from previous 
medical specialists such as multiple radiographic scans, biopsy 
results, and pulmonary function. Surgeons need an accu-
rate and well calibrated predictive model to help diagnose a 
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suspected lung cancer without missing early stage disease; no 
models exist which integrate this additional information.19 We 
developed and validated the Thoracic Research Evaluation And 
Treatment (TREAT) lung cancer prediction model and com-
pared the performance of the TREAT model to the Mayo Clinic 
model in two populations being evaluated for lung resection.
METHODS
Study Population
The TREAT model was developed in the Vanderbilt 
University Medical Center (VUMC) Lung Cancer Cohort 
and to examine the generalizability of the TREAT model, it 
was validated in the Tennessee Valley Veterans Affairs (VA) 
cohort. The Vanderbilt cohort was composed of patients iden-
tified from two separate sources. Using VUMC’s Thoracic 
Surgery Quality Improvement database and clinic records, 
606 patients were identified who received an evaluation of 
a lung nodule or mass by a thoracic surgeon for known or 
suspected non–small-cell lung cancer from January, 2005 to 
October, 2010 (Fig. 1). Demographic and clinical data for 
each procedure were abstracted using the Society of Thoracic 
Surgeons National Database for General Thoracic Surgery 
specifications and guidelines.20 Imaging data were abstracted 
from radiologist reports or from original scans of the most 
recent preoperative CT scans for lesion growth, edge char-
acteristics, and F18-fluorodeoxyglucose (FDG)-positron 
emission tomography (PET) avidity by experienced medical 
reviewers.5,18,21,22 Lesion edge characteristics defined by the 
terms smooth, lobulated, lobular, lobed, irregular, ground 
glass opacity, ground glass nodule, spiky, or spiculated in the 
radiologists’ reports were designated by medical reviewers as 
either smooth, lobulated, ground glass opacity, spiculated, or 
indeterminate. The growth on serial radiographs occurring 
at least 60 days apart is defined as an increase in the mean 
diameter of 2 mm for nodules initially less than 15 mm in size 
and an increase of at least 15% compared with a baseline 
scan for lesions more than 15 mm in size at baseline.23 For 
cases with one preoperative radiograph or whose subsequent 
radiograph was fewer than 60 days and deemed too short a 
time span to record lesion growth, the case was designated 
as “insufficient data.” FDG-PET avidity was determined by 
either physician report or by maximum standard uptake value 
(SUV). Not avid was coded if the radiologist report used the 
terminology: not avid, not cancerous, low avidity, not likely 
cancerous or reported a SUV less than 2.5. Avidity was coded 
if the radiologist used the terminology: avid, likely cancerous, 
highly avid, cancerous or reported a SUV of 2.5 or greater. 
Any radiological reports of insufficient quality to determine 
diagnosis, shape characteristics, or FDG-PET avidity by chart 
review were reviewed for determination by a thoracic surgeon. 
If no designation could be made, then the original scans were 
reviewed by a thoracic radiologist blinded to clinical pretest 
data and pathological outcome. Diagnosis was confirmed by 
the pathologic examination after thoracotomy, thoracoscopy, 
mediastinoscopy, bronchoscopy with biopsy (N = 523) or 
by radiographic surveillance among patients not undergoing 
a procedural biopsy (N = 83). Preoperative symptoms were 
defined as any documented evidence in the medical record 
of the following: hemoptysis, shortness of breath, unplanned 
weight loss, fatigue, pain, or pneumonia. Preoperative pre-
dicted forced expiratory volume in 1 second (FEV
1
) was a 
continuous variable based on the most recent pulmonary func-
tion test prior to their thoracic operation.
Individuals with multiple nodules or who had the evi-
dence for benign diseases (e.g., benign calcification, infil-
trates, bronchiolitis obliterans organizing pneumonia, or 
empyema) were excluded (N = 39). Also, individuals receiving 
an operation for a known malignancy after initial chemo-radi-
ation therapy (N = 13), who had no preoperative radiographic 
FigurE 1.  Consort diagram of VUMC and 
Tennessee Valley Healthcare System VA cohort. 
VUMC, Vanderbilt University Medical Center cohort; 
VA, Veteran Affairs; NSCLC, non–small-cell lung 
cancer.
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imaging documentation to determine evaluation rationale 
(N = 13), those with known metastatic disease (N = 5), indi-
viduals without a definitive clinical diagnosis after surgery 
(N = 1) or reoperation (N = 1) were excluded. Nonsurgical 
patients with less than 2 years of radiographic surveillance or 
clinical follow-up from the date of their surgical evaluation 
(N = 38) were excluded as were nonsurgical patients with mul-
tiple or calcified nodules (N = 4). The remaining 492 patients 
were used in our analysis. Vanderbilt University Institutional 
Review Board approved this study with a waiver of individual 
patient consent.
The Tennessee Valley Veterans Affairs Cohort was com-
posed of 245 individuals receiving a thoracic operation for 
known or suspected lung cancer between January 1, 2005 and 
December 31, 2013. Individuals with no preoperative radio-
graphic imaging documentation to determine evaluation ratio-
nale (N = 10), those with known metastatic disease (N = 4), 
individuals without a definitive clinical diagnosis after sur-
gery (N = 2), known benign disease (N = 1), mesothelioma 
(N = 1), or reoperation (N = 1) were excluded. The remain-
ing 226 patients were used to validate the TREAT model. 
Tennessee Valley Healthcare System—Veteran’s Affairs 
Institutional Review Board approved this study.
Selection of Variables for the Model
The TREAT model was developed using a prespecified 
set of candidate variables derived from previously published 
and validated models for determining appropriate screening 
populations for low-dose CT scans,13 or for estimating the 
likelihood a lung nodule is malignant after its discovery14–16 
(Table 1). Lesion growth and FDG-PET scan avidity were 
chosen due to their inclusion in recent guidelines for diag-
nosis and that a patient should be referred for surgical evalu-
ation when they occur.17 Additional variables for the TREAT 
model were chosen after consulting with thoracic surgeons as 
to those factors commonly encountered in their practice and 
that influence their risk estimates, given the radiographic dis-
covery of a lung nodule or mass.
Statistical Analysis
Analyses were performed in R v3.0.1 and Stata v12 
(College Station, TX). Variables were summarized and exam-
ined as appropriate in numerical (e.g., mean, median, or pro-
portion) and graphical fashion (scatter plots, boxplots, or 
histograms). Descriptive statistics and the extent of missing 
data are reported in Table 1. Analysis of demographic vari-
ables and prespecified predictors of lung cancer according to 
lung cancer status were conducted utilizing only the observed 
data. Multiple imputation techniques and predictive mean 
matching were used for imputation of the missing values.24 
Multiple imputation assumptions were examined following 
the methods of Potthoff et al.25
Logistic regressions models for predicting lung can-
cer were fit to the data and evaluated for accuracy, calibra-
tion, and overfitting based on the methodology of Harrell 
and Steyerberg.24,26 Nonlinear associations between continu-
ous variables and lung cancer were evaluated using restricted 
cubic splines of three and five knots, and linearity was tested 
using the likelihood ratio test. The model’s ability to dis-
criminate between cancer and benign disease was evaluated 
by the area under the receiver operating characteristic curve 
(AUC). Model calibration, in the sense of directly compar-
ing a model’s predicted probabilities to observed probabili-
ties, was assessed with Brier score of the model’s predictions. 
Bootstrap methods were used to (1) obtain standard errors for 
the model parameters and model predictions, and (2) assess 
the degree of optimism of the model’s accuracy to predict 
cancer. A stable, internally valid TREAT model was corrected 
for optimism, which occurs due to overfitting of the model, 
by using the bootstrap with replacement approach. AUC and 
Brier score performance used 500 bootstrap iterations with 
replacement for the TREAT model.27 AUC and Brier score for 
the Mayo Clinic model were estimated using the published 
equation of variable coefficients from the original article.14 
The Mayo Clinic model’s probability of a malignant pulmo-
nary nodule equals ex/(1 + ex); where x = −6.8272 + (0.0391 × 
age) + (0.7917 × smoking history) + (1.3388 × previous non-
thoracic cancer) + (0.1274 × lesion size) + (1.0407 × spicu-
lated lesion edge) + (0.7838 × upper lobe location). The AUC 
and Brier for the Mayo Clinic model were compared with the 
AUC and Brier of the bootstrapped TREAT model in both the 
VUMC development and the VA validation datasets.
TAblE 1.  Variables Used in Published, Validated Clinical 
Lung Cancer Prediction Models
Model PLCO
M2012
Mayo 
Clinic VA
SPN  
Model TREAT
Variables
Age √ √ √ √ √
Sex √ √
Race √
Education √
Body mass index √ √
COPD √ √b
Family history of cancer √
Smoking (Y/N) √ √ √
Smoking—pack years √a √ √
Years quit smoking √ √
Hemoptysis √ √c
Previous cancer √ √ √
Lesion size √ √ √ √
Lesion growth √ √
Spiculation √ √ √
Lesion location √ √ √
FDG-PET avidity √ √
PLCO
M2012
 Model was developed to estimate risk of lung cancer in a healthy 
population for purposes of determining who should be screened. The Mayo Clinic, VA, 
SPN model, and TREAT models were developed to estimate lung cancer risk given 
radiographic detection of a SPN.
aPack years were separated out into smoking duration and smoking intensity.
bCOPD modeled using predicted forced expiratory volume in 1 sec as a continuous 
variable.
cHemoptysis included in preoperative symptoms which also included any of: 
shortness of breath, unplanned weight loss, fatigue, pain, or pneumonia.
VA, Veteran Affairs; SPN, solitary pulmonary nodule; TREAT, Thoracic Research 
Evaluation And Treatment; COPD, chronic obstructive pulmonary disease; FDG-PET, 
F18-fluorodeoxyglucose positron emission tomography.
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rESulTS
Lung cancer prevalence in the VUMC cohort (N = 492) 
was 72% and 93% in the VA cohort (N = 226). Pathological 
diagnosis after resection occurred in 451 (92%) and by active 
surveillance in 41 (8%) individuals in the VUMC cohort 
and all diagnoses in the VA cohort were determined patho-
logically. Complete covariate data were available for 264 and 
136 individuals in the VUMC and VA cohorts, respectively. 
Those with a cancer diagnosis were more likely to have com-
plete data (58%) than those with the benign disease (42%) 
in the development cohort. Missing data for FDG-PET 
and FEV
1
 were more common among those patients in the 
VUMC cohort diagnosed by active surveillance (85% and 
61%, respectively). Missing data occurred most often with 
FDG-PET scan (22% in VUMC and 21% in VA), growth on 
serial CT scans (13% in VUMC and 1% in VA), predicted 
FEV
1
 (10% in VUMC and 0% in VA) and preoperative dis-
ease symptoms (7% in VUMC and 16% in VA). The remain-
ing variables of interest had less than 5% missing data in 
the VUMC development dataset. Assumptions regarding the 
missing data did not preclude the use of multiple imputation 
according to Potthoff ’s methodology.25 The VA cohort pre-
dominantly consisted of men (97%), had a higher prevalence 
of preoperative symptoms (62%), were more likely to smoke 
(95%) and smoked more (50 pack-years), had slightly larger 
lesions on average (29 mm) and those lesions were more 
likely to be FDG-PET avid (95%) when compared with the 
VUMC cohort (Table 2).
In the TREAT model, lung cancer risk increased with 
age, preoperative lesion size, lesion growth, previous cancer, 
and FDG-PET avidity (Table 3). Smoking intensity measured 
by pack-years had a nonlinear relationship with lung cancer 
and thus was modeled as a restricted cubic spline (Table 3). 
The initial model development, prior to bootstrapping, for the 
TREAT model produced an AUC of 0.89 (95% confidence 
interval [CI], 0.86–0.92) and Brier score of 0.11. Internal 
validation with bootstrap adjustment resulted in an AUC of 
0.87 (95% CI, 0.83–0.92) and Brier score of 0.12 (95% CI, 
0.10–0.14). In the VA validation cohort, the AUC for the boot-
strapped TREAT model was 0.89 (95% CI, 0.79–0.98) and 
Brier score was 0.08 (95% CI, 0.06–0.10).
The Mayo Clinic model on the VUMC cohort, using 
published coefficients to estimate lung cancer risk (Table 3), 
had an AUC of 0.80 (95% CI, 0.75–0.85) which was sig-
nificantly less (p < 0.001) than the AUC observed for the 
TREAT model (Fig. 2). The Mayo Clinic model generally 
overestimated the risk and its Brier score was 0.17 (95% 
CI, 0.15–0.19), showing poorer calibration than the TREAT 
model (Fig. 3) on the VUMC cohort. The AUC for the Mayo 
Clinic model on the VA cohort was 0.73 (95% CI, 0.60, 
0.85) and Brier score was 0.18 (95% CI, 0.15–0.21). AUC 
and Brier score in the validation dataset were improvements 
over that found in the development dataset. The Mayo Clinic 
model on an average predicted a slightly higher probability 
of lung cancer compared to the TREAT model in individu-
als with no growth and a higher risk for lung cancer when 
compared with the TREAT model among individuals with 
non-avid FDG-PET scans.
DiSCuSSiON
Clinicians evaluating pulmonary nodules are faced with 
a basic question of equipoise. Unlike biopsy for breast, pros-
tate, or colon cancer, the lung nodule is difficult to access, and 
lung biopsy has significant risks associated with the procedure. 
Reviews of outcomes after lung surgery have found 1 to 3% 
mortality rates within 30 days and rates as high as 7% at 90 
days.4,28–30 If the patient under evaluation has marginal lung 
function and other preoperative comorbidities, then the likeli-
hood of a poor outcome increases. This procedural risk is juxta-
posed against the danger of missing a curable lung cancer. One 
suggested solution is for the clinician to delay biopsy and treat-
ment until a more definitive noninvasive diagnosis is possible. 
The effects of diagnosis and treatment delay from the time of 
lesion discovery to stage progression and metastasis is not well 
known.31 Thus, clinical practice typically focuses on timeliness 
of care even for a small and localized cancer. We propose a 
new, validated clinical prediction model for lung cancer in a 
patient population with lung nodules being evaluated for a sur-
gical lung biopsy. The TREAT lung cancer model provided a 
high and consistent predictive discrimination for lung cancer 
based on common clinical characteristics and performed better 
TAblE 2.  Demographic and Radiological Data in VUMC 
Development and VA Validation Datasets
VUMC
N = 492
VA
N = 226
Male (%) 192 (51) 220 (97)
Caucasian (%) 453 (92) 196 (87)
  Missing 2 2
Mean age (SD) 63 (13) 65 (8)
Smoking status—ever (%) 378 (77) 215 (95)
Median pack—years among smokers (IQR) 42 (30, 60) 50 (44, 85)
  Missing 8 3
Mean BMI, kg/m2 (SD) 27.7 (6) 26 (5)
  Missing 2 2
Mean predicted FEV
1
 (SD) 77.7 (20) 72.0 (17)
  Missing 50 0
Preoperative symptomsa (%) 118 (26) 117 (62)
  Missing 33 37
Previous cancer (%) 181 (37) 57 (25)
Upper lobe location (%) 283 (59) 77 (34)
  Missing 13 0
Mean lesion size, mm (SD) 28 (19) 29 (17)
Growth (%) 200 (47) 90 (40)
  Missing 65 2
Spiculation 214 (45) 141 (65)
  Missing 19 10
FDG-PET avidity (%) 328 (86) 170 (95)
  Missing 109 47
Patients with complete data (%) 264 (58) 136 (60)
aPreoperative symptoms included any of: hemoptysis, shortness of breath, unplanned 
weight loss, fatigue, pain, or pneumonia.
FEV
1
, forced expiratory volume in 1 sec; VUMC, Vanderbilt University Medical 
Center; VA, Veteran Affairs; IQR, interquartile range; BMI, body mass index; FDG-PET, 
F18-fluorodeoxyglucose positron emission tomography.
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than the Mayo Clinic model. The TREAT model’s high level of 
discrimination may be valuable in providing clinical guidance 
in estimating individual likelihood of lung cancer.
We identified superior performance of the TREAT lung 
cancer model (AUC = 0.87; 95% CI, 0.83–0.92) compared with 
the Mayo Clinic model (AUC = 0.80; 95% CI, 0.75–0.85) and 
validated the TREAT model (AUC = 0.89) in a separate cohort 
with a higher prevalence of the disease and a higher acuity 
from a nearby Veterans Affairs institution. The Mayo Clinic 
model performed well in the VUMC population although the 
prevalence of disease in our cohort was higher (72%) than in 
the population in which the Mayo Clinic model was developed 
(23%) and validated (44%).14–16 As the prevalence of disease 
increased to 95%, as was found in the VA validation cohort, 
the accuracy of the Mayo Clinic model to discriminate malig-
nancy decreased (AUC = 0.73). The calibration of the Mayo 
Clinic model, as measured by the Brier score, also decreased 
as the prevalence of the disease increased in the two cohorts 
for surgical evaluation. The Mayo Clinic model appears to 
underestimate the risk for cancer in the lower quintiles of lung 
cancer risk in these populations which limits its use in clinical 
practice for patients being evaluated for surgery.18 Two factors 
are clear. First, the population being evaluated by surgeons has 
a higher prevalence of lung cancer than other lung nodule–
evaluated populations.9,22,32 Second, the guideline suggested 
model for estimating the likelihood of malignancy is less 
accurate in terms of discrimination and calibration in these 
two surgical populations.
The addition of FDG-PET avidity and lesion growth as 
predictive variables contributed to the TREAT model’s supe-
rior discrimination. Exploratory analyses of the model with 
Bland–Altman plots showed that PET avidity and growth 
TAblE 3.  Estimated Model Coefficients for Mayo Clinic and TREAT Models
Mayo Coefficient TREAT Coefficienta TREAT Odds Ratio (95% CI) p Value
Constant −6.827 −4.715
Age (per year) 0.0391 0.0533 1.05 (1.03–1.08) <0.001
BMI — −0.0262 0.97 (0.93–1.02) 0.24
Sex—male — −0.0547 0.95 (0.55–1.64) 0.84
Pack-years — a b 0.02
Smoking history (yes/no) 0.792 — — —
Lesion size(per mm) 0.127 0.0577 1.06 (1.04–1.08) <0.001
Spiculated lesion edge 1.041 0.277 1.32 (0.73–2.40) 0.26
Lesion location–upper lobe 0.784 −0.015 1.02 (0.58–1.78) 0.99
Lesion growth
  No lesion growth — Reference Reference —
  Insufficient data — 0.259 1.29 (0.56–2.79) 0.59
  Growth observed — 1.160 3.18 (1.58–6.39) 0.003
Previous cancer 1.339 0.639 1.89 (1.05–3.42) 0.03
Predicted FEV
1
— −0.013 0.99 (0.97–1.00) 0.07
Any preoperative symptoms — −0.461 0.63 (0.33–1.20) 0.16
FDG-PET Avid — 1.834 6.26 (2.78–14.1) <0.001
aProbability{lung cancer = 1}  = ex/(1 + ex); where x = −4.715 + 0.0533 × (Age) – 0.0262 × (BMI) − 0.0547 × (sex: male) + 0.02338 × (pack-years) − 0.000003 × pack-years( )
+
3  + 
0.000006 × + 0.000003 × pack-years 80−( )
+
3 + 0.0577 × (lesion size) + 0.277 × (speculated lesion) + 0.015 × (lesion location) + 0.259 × {lesion growth: insufficient data} + 1.160 × 
{lesion growth: growth observed} + 0.639 × (previous cancer) − 0.013 × (predicted FEV
1
) − 0.461 × (any symptoms) + 1.834 × (FDG-PED Avid) and {c} = 1 if subject is in category 
c, 0 otherwise; ( ) ( ) ,pack-years x pack-years x   if (pack-years x)  o− − −+ = >
3 3 3 0 0 therwise.
bPack-years is modeled as a restricted cubic spline and therefore odds ratios are not directly interpretable.
TREAT, Thoracic Research Evaluation And Treatment; CI, confidence interval; FEV
1
, forced expiratory volume in 1 sec; BMI, body mass index; FDG-PET, F18-fluorodeoxyglucose 
positron emission tomography.
FigurE 2.  Comparison of AUC for the Mayo Clinic model using 
originally published estimates and TREAT model in the VUMC and 
VA cohorts. CIs for AUC are reported for each estimate model. 
TREAT model AUC is significantly higher compared with the 
Mayo Clinic model in each cohort (p < 0.001). AUC, area under 
the receiver operating curve; TREAT, Thoracic Research Evaluation 
And Treatment; VA, Veteran Affairs; VUMC, Vanderbilt 
University Medical Center cohort; CI, confidence interval.
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accounted for the majority of differences in prediction between 
the two models in the VUMC cohort (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A655). The differences 
in predicted cancer risk between the two models were consis-
tent across bootstrap generated datasets (Supplemental Digital 
Content 2, http://links.lww.com/JTO/A655). The TREAT 
model takes advantage of this additional information avail-
able to surgeons at the time of the evaluation. The addition 
of FDG-PET, lesion growth, predicted FEV
1
, and presenta-
tion with any symptoms improved the discrimination between 
benign disease and lung cancer.
At this time our findings have some limitations. The 
cohort used for model development was a retrospective review 
of a single tertiary academic medical center’s database contain-
ing prospectively collected information supplemented by med-
ical chart review for specific variables. The external validation 
cohort had a high prevalence of disease and the observed 
improvement in discrimination is likely due, in part, to the high 
prevalence of cancer in this cohort. This cohort was primarily a 
Veteran population, so there were more men smokers with pre-
operative symptoms. These differences did not result in a drop 
in the AUC or Brier score and may improve the generalizability 
of the model. Other surgical populations being evaluated for 
lung resection may have differing prevalence of the disease, 
referral patterns, radiologist expertise or other underlying fac-
tors, like endemic granulomatous disease which are important 
considerations for clinical prediction models intended to apply 
to more than a single institution.22 The impact of these pos-
sible predictors of lung cancer is relevant to future work as the 
TREAT model is validated in other populations.
As in most clinical datasets used for association stud-
ies or predictive models, missing data for the predictors of 
interest is a constraint in our study. In the development of the 
TREAT model, statistical methods were used to impute miss-
ing variables and analyses determined the impact of this miss-
ing data on the model. We chose to include 41 patients who 
did not have a surgical resection and underwent radiographic 
surveillance. Including these patients increased the missing 
data in the cohort, but more importantly, excluded a bias in 
the spectrum of risk encountered by clinicians and minimized 
the additional bias arising from patients not undergoing resec-
tion. For example, predicted FEV
1
 is generally not performed 
unless resection is likely as clinical quality guidelines suggest 
performing pulmonary function tests prior to lung resection. 
This pattern of work-up bias between the individuals indicates 
that the data may not be missing at random. The multiple 
imputation algorithm used depends on the missing at random 
assumption given known covariate patterns, and our investi-
gation of this assumption did not yield any indications that 
would be concerning. In a sensitivity analysis, TREAT model 
results with only complete data which was similar to that esti-
mated using imputed data.
Although little difference was observed in the bootstrap 
adjusted AUC or Brier scores when compared with the initial 
estimates of AUC and Brier score, the model must be vali-
dated in independent, external populations prior to use in the 
clinical setting. Other cohorts for external validation of the 
TREAT model should have differing prevalence of the disease 
and from other regions of the country to assess the generaliz-
ability of the TREAT model in aiding surgeons evaluating a 
lung nodule.
The prediction model developed by Bach et al.,10 the 
Liverpool model33 and that developed by Tammemägi et al.13 
are intended to determine who would most benefit from lung 
cancer screening. The Mayo Clinic, the VA Lung Cancer and 
the solitary pulmonary nodule models for characterizing lung 
FigurE 3.  Box plots comparing Brier score from 
500 bootstrap samples of the data for each model 
and from each cohort. Brier score for the TREAT 
model exhibited better calibration of predicted 
probability of lung cancer when compared with 
the Mayo Clinic model in the VUMC cohort (TREAT 
= 0.12 versus Mayo Clinic = 0.17) and VA cohort 
(TREAT = 0.07 versus Mayo Clinic 0.18). Brier score 
values of 0.25 are the same as a chance and lower 
values of Brier score represent increased calibration 
of the model. As Brier score decreases from 0.25 to 
0, the predicted probability of cancer increasingly 
equals the observed probability of cancer and the 
calibration is improved. TREAT, Thoracic Research 
Evaluation And Treatment; VUMC, Vanderbilt 
University Medical Center cohort; VA, Veteran 
Affairs.
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nodules after their discovery for surgical biopsy were devel-
oped and validated in populations with lower prevalences 
of lung cancer than observed here.15–17 A recently published 
model to characterize the likelihood, a screening discovered 
lung nodule was cancerous had an extremely high AUC of 
0.94, but it was developed and calibrated in screening popula-
tions with a 5.5% prevalence of lung cancer.34 When examin-
ing the landscape of clinical prediction models for lung cancer, 
clinicians evaluating a patient immediately prior to surgery 
have no validated models for this high risk population.35 The 
TREAT model addresses that need. Future work will validate 
the TREAT model in external datasets with varying preva-
lence of malignancy to measure the changes in the negative 
predictive value of the model. Application of the TREAT 
model in the clinical setting requires prospective evaluation of 
the model to determine those cut points of the predicted risk 
that both minimizes the risk of missing a lung cancer with the 
harms of a futile thoracotomy.
CONCluSiON
In a population with a radiographically confirmed lung 
lesion being evaluated for possible resection, the TREAT 
model predicted the risk for lung cancer with high accuracy 
and an AUC of 0.87. The model was validated and showed 
little overfitting in its accuracy to discriminate between lung 
cancer and benign disease. The TREAT model incorporates 
the full spectrum of epidemiologic and radiographic evidence 
available to surgeons in the United States today, and it bet-
ter predicts lung cancer with a higher AUC than existing 
published models. This model will be validated in additional 
external datasets and if valid, applied in a prospective study to 
reduce unnecessary pulmonary resections.
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